- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03428295
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
Assessments of Hybrid Closed Loop and Fully Automated Closed Loop Dose Safety Artificial Pancreas Device in Type 1 Diabetes in a Hospital Clinical Research Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3.1 Overview Two independent questions will be addressed in this study. For evaluation of the safety and efficacy of the hybrid closed loop (HCL), participants will use the hybrid closed loop during and after a standardized meal on the clinical research center. For evaluation of the safety and efficacy of the fully automated closed loop (FACL), participants will use the system for a 24 hour clinical research center stay incorporating meals and standardized exercise. Safety and efficacy will be evaluated by descriptive outcomes including number of completed studies and glycemic control.
3.2 Eligibility. Participants will be recruited from the Diabetes Registry at the Benaroya Research Institute. Eligibile participants may enroll in the HCL, the FACL, or both studies.
HCL Study visit, Day 1 (~7 hours total): The below times are approximate and may be adjusted to accommodate the CRC schedule. Prior to arrival at the CRC, participants will be asked to eat their normal breakfast and take their usual amount of insulin based on BG and carbohydrate content before 8am. Once at the CRC, participants will be able to drink water ad lib, but no food other than the prescribed meals can be eaten, unless hypoglycemia intervention is necessary. Participants will be required to check FSBG before the meal and calibrate if the FSBG value varies by >30% from CGM value.
FACL Study visit, Day 1 (~ 23 hours total): The below times are approximate and may be adjusted to accommodate the CRC schedule. Prior to arrival at the CRC, participants will be asked to eat their normal breakfast and take their usual amount of insulin based on BG and carbohydrate content before 8 am. Once arrived at the CRC, participants will be able to drink water, but no food other than the prescribed meals can be eaten, unless hypoglycemia intervention is necessary. Participants will be required to check FSBG before meals, at bedtime and at 0300. They will calibrate if the FSBG value varies by >30% from the CGM value. They will calibrate the CGM every 12 hours as recommended by Dexcom.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Redmond, Washington, United States, 98052
- Dose Safety
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must have type 1 diabetes for greater than 1 year
- Have a hemoglobin A1c less than 9.0%
- Participants in the FACL arm must report that they engage in aerobic exercise at least 30 minutes three times weekly
- If participants in the FACL arm are age >35 OR duration of T1D >15 years OR history of T1D complications (proliferative retinopathy, nephropathy, peripheral vascular disease, autonomic neuropathy), participant must have EKG within normal limits obtained within last 6 months of study date
- Age 18-70
- Fluent and literate in English
- Use of an insulin pump for ≥ 3 months
- Use of a CGM/sensor for ≥ 5 days/week for ≥3 months
- Must have a diabetes care provider
- Use of an effective birth control method for women who are sexually active and of childbearing potential
- Willing and able to give informed consent
Exclusion Criteria:
- History of ≥ 1 episode of severe hypoglycemia (defined as hypoglycemia leading to loss of consciousness, seizure, or requiring assistance) in the previous 6 months
- History of ≥ 1 episode of DKA in the previous 6 months
History of cardiovascular disease, characterized by any of the following:
- Prolonged QT or arrhythmia
- History of myocardial infarction within the past 6 months
- History of ischemia on functional cardiac exam within the last year
- History of left ventricular ejection fraction < 30%
- Uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg)
- Current use of a beta blocker
- Stage 3 or greater renal disease
- Untreated thyroid disease
- History of substance abuse
- Current or previous use of medications for control of a seizure disorder
- Enrolled in another clinical trial in which they received investigational drug in the last 12 weeks
- Inability to comply with protocol
- Pregnant or breast feeding
- Use of medications other than insulin to control glucose
- Chronic corticosteroid use
- Pre-existing medical conditions deemed by study investigator to interfere with the study or increase risks of study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Single Cohort in CRC
This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
|
Device will be used to automatically dose insulin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of time in hypoglycemic range
Time Frame: 36 hours
|
defined as <70 mg/dL
|
36 hours
|
Percentage of time in severe hyperglycemic range
Time Frame: 36 hours
|
defined as >/=250 mg/dL
|
36 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- APS4
- 2R44DK104317-03 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose, Low Blood
-
Wageningen University and ResearchCompletedGlucose, Low Blood | Glucose, High BloodNetherlands
-
Ingredion IncorporatedKGK Science Inc.CompletedGlucose, Low Blood | Glucose, High Blood | Meals
-
Izmir Bakircay UniversityEge UniversityCompletedBlood Glucose, LowTurkey
-
Matthew GroutCompletedMood | Cognitive Performance | Glucose, Low Blood | Glucose, High BloodUnited Kingdom
-
Matthew GroutCompletedDiet Modification | Mood | Glucose, Low Blood | Glucose, High Blood
-
University of ViennaCompletedHunger | Blood Glucose, LowAustria
-
Weizmann Institute of ScienceCompletedGlucose Intolerance | Glucose, Low Blood | Glucose, High BloodIsrael
-
Coombe Women and Infants University HospitalRecruitingFasting | Glucose, Low Blood | Cesarean Delivery Affecting FetusIreland
-
KK Women's and Children's HospitalActxa Pte LtdCompletedBlood Glucose, High | Blood Glucose, LowSingapore
-
Shaheed Benazir Bhutto University Sheringal Dir...Khyber Medical University PeshawarCompletedHypoglycemia | Blood Glucose, LowPakistan
Clinical Trials on Dose Safety AP system
-
Apollo Endosurgery, Inc.CompletedObesityUnited Kingdom, Australia, United States, Italy, Canada, Belgium
-
Oregon Health and Science UniversityJuvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable...Completed
-
Apollo Endosurgery, Inc.Completed
-
Sansum Diabetes Research InstituteUniversity of California, Santa BarbaraCompletedType 1 Diabetes MellitusUnited States
-
ONL TherapeuticsActive, not recruitingOpen Angle GlaucomaAustralia, New Zealand
-
Haukeland University HospitalCompletedPostoperative Complications | Complications of Surgical Procedures or Medical CareNorway
-
Inreda Diabetic B.V.Stichting Robopump; Rijnstate ziekenhuis; Kinder Diabetes Centrum NijmegenCompletedDiabetes Mellitus, Type 1Netherlands
-
University of Massachusetts, WorcesterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedPost Traumatic Stress Disorder | Alcohol Use DisorderUnited States
-
Aalborg University HospitalAalborg UniversityCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType1 Diabetes MellitusUnited States